62492-80-2

Upstream product

• 15761-38-3 L-N-Boc-Ala 
• 2835-77-0 (2-aminophenyl)(phenyl)methanone 
• 1082051-52-2 tert-butyl 1-(2-benzoylphenylamino)-1-oxopropan-2-ylcarbamate 
• 119-61-9 benzophenone 
• 39859-36-4 2-amino-5-bromobenzophenone 
• 872873-91-1 S-[1-(2-benzoyl-phenylcarbamoyl)-ethyl]-carbamic acid tert-butyl ester 
• 754163-02-5 C₁₆H₁₆N₂O₂ 

Downstream Products

• 918159-84-9 (3S)-(+)-1-di(p-anisyl)methyl-1,3-dihydro-3-methyl-5-phenyl-2H-1,4-benzodiazepin-2-one 
• 939784-05-1 C₃₇H₃₃N₂O₅P 
• 939784-08-4 C₂₈H₂₈N₂O₄ 
• 939784-07-3 C₃₂H₃₉N₂O₄P 
• 872873-92-2 SH-I-030 
• 34099-65-5 7-bromo-3-methyl-5-phenyl-1,3-dihydro-benzo[e][1,4]diazepin-2-one 

Relevant academic research and scientific papers

Design and synthesis of benzodiazepine analogs as isoform-selective human lysine deacetylase inhibitors

A comprehensive investigation was performed to identify new benzodiazepine (BZD) derivatives as potent and selective human lysine deacetylase inhibitors (hKDACis). A total of 108 BZD compounds were designed, synthesized and from that 104 compounds were biologically evaluated against human lysine deacetylases (hKDACs) 1, 3 and 8 (class I) and 6 (class IIb). The most active compounds showed mid-nanomolar potencies against hKDACs 1, 3 and 6 and micromolar activity against hKDAC8, while a promising compound (6q) showed selectivity towards hKDAC3 among the different enzyme isoforms. An hKDAC6 homology model, refined by molecular dynamics simulation was generated, and molecular docking studies performed to rationalize the dominant ligand-residue interactions as well as to define structure-activity-relationships. Experimental results confirmed the usefulness of the benzodiazepine moiety as capping group when pursuing hKDAC isoform-selectivity inhibition, suggesting its continued use when designing new hKDACis.

SELECTIVE ANTICONVULSANT AGENTS AND THEIR USES

In preferred embodiments, the present invention provides methods of treatment and pharmaceutical compositions for the suppression, alleviation and prevention of seizures. The preferred embodiments of the present invention further relate to methods of treatment and pharmaceutical compositions using benzodiazepine derivatives that provide suppression, alleviation and prevention of seizures with reduced sedative and ataxic side effects.

Novel 1,4-benzodiazepine derivatives with antiproliferative properties on tumor cell lines

Novel 1,4-benzodiazepine compounds were synthesized and evaluated for their ability to inhibit the proliferation of tumor cells. Some compounds revealed activities in the micromolar range and were more efficient than reference compound Ro 5-4864. Prelimin

Stereospecific anxiolytic and anticonvulsant agents with reduced muscle-relaxant, sedative-hypnotic and ataxic effects

The present invention provides compositions and methods of using stereospecific benzodiazepine derivatives, their salts and prodrugs for the treatment of anxiolytic or convulsant disorders having the side effects of reduced alcohol craving in human alcoholics and a concomitant reduced sedative, hypnotic, muscle relaxant and ataxic side-effects. The invention further provides pharmaceutical compositions for treatment of anxiolytic and convulsant disorders in subjects in need thereof, comprising a compound, prodrug or a salt having a chemical structure represented by any one of Formula I-XXI and a pharmaceutically-acceptable carrier.